Farmax India Limited Announces Unaudited Standalone Earnings Results for the Second Quarter and Six Months Ended September 30, 2015
For the Sox months, the company reported total income from operations of INR 106.174 million against INR 71.366 million a year ago. Loss from operations before other income, provisions and exceptional items were INR 42.195 million against INR 53.541 million a year ago. Loss from ordinary activities before tax was INR 40.789 million against INR 52.295 million a year ago. Net loss after taxes, minority interest and share of profit of associates was INR 40.789 million or INR 0.08 per basic and diluted share before and after extraordinary items not annualized against INR 52.295 million or INR 0.06 per basic and diluted share before and after extraordinary items not annualized a year ago.